Our Research

We invest in the next generation of leukaemia research talent. With your help we fund cutting-edge research from some of the brightest minds in the UK and beyond, which is crucial to finding breakthroughs and cures for leukaemia and blood cancers.

Filter location by:

Professor Dominique Bonnet

Francis Crick Institute, London

Find out more

Professor Richard Clark

University of Liverpool

Find out more

Professor Francesco Dazzi (Vice Chair)

King’s College London

Find out more

 Professor John Gribben

Queen Mary University of London

Find out more

Professor Olaf Heidenreich

Newcastle University 

Find out more

Professor Anastasios Karadimitris

Imperial College London


Find out more

Professor Ken Mills

Queen’s University Belfast

Find out more

Professor Emma Morris

University College Hospital, London 

Find out more

 Professor Katy Rezvani

MD Anderson Cancer Centre, Texas, USA 

Find out more

Professor Nick Cross (Chair)

University of Southampton

Find out more

Professor Jackie Boultwood

University of Oxford

Find out more

Professor Tariq Enver

University College London

Find out more

Professor Maria Figueroa

University of Miami Miller School of Medicine, USA

Find out more

Dr. Steve Devine MD

CIBMTR, Minneapolis, USA

Find out more

Dr. Bipin Savani MD 

Vanderbilt University Medical Center, USA

Find out more

Dr. Bronwen Shaw MD 

Medical College of Wisconsin, USA

Find out more

Lorna Jackson

Glasgow, UK

Find out more

Mansi Manij Shah 

Birmingham, United States

Find out more

Marcin M. Machnicki 

Warsaw, Poland

Find out more

Vanessa L. Porter 

Vancouver, Canada

Find out more

Chetasi Talati 

Tampa, USA

Find out more

Flavia Vasconcelos

Rio De Janeiro, Brazil

Find out more

Francesco Autore

Rome, Italy

Find out more

Aditya Singh

Punjab, India

Find out more

Tanmoy Kumar Mandal 

Mumbai, India

Find out more

Co Nguyen Phuong Dung

Ho Chi Minh City, Vietnam

Find out more

Prof Ken Mills

Queen's University, Belfast

Find out more

Dr Jasper de Boer

UCL Institute of Child Health

Find out more

Prof Jaqueline Boultwood

University of Oxford

Find out more

Dr Dinis Calado

Francis Crick Institute

Find out more

Dr Fernando Afonso

ECSCRI, Cardiff

Find out more

Dr Beth Payne

Cancer Institute, UCL

Find out more

Dr Lisa J Russell

Newcastle University

Find out more

Dr Salima Nurohamed

University of Oxford

Find out more

Dr Vignir Helgason

University of Glasgow

Find out more

Dr Edwin Chen

University of Leeds

Find out more

Dr Javier Redondo Muñoz

University of Manchester

Find out more

Dr Matthew Rose-Zerilli

University of Southampton

Find out more

Dr Sergey Krysov

Barts Cancer Institute

Find out more

Dr Xu Huang

University of Glasgow


Find out more

Dr Lisa Hopcroft

University of Glasgow

Find out more

Dr Lisa Hopcroft

University of Cambridge

Find out more

Dr Maria Teresa Esposito

University of East London

Find out more

Dr Anjali Kusumbe

University of Oxford

Find out more

Dr. Kristina Kirschner

University of Glasgow

Find out more

Dr Sarah Dimeloe

University of Birmingham

Find out more

Research is crucial to improving the lives of people with leukaemia. The development of the drug Imatinib to successfully treat Chronic Myeloid Leukaemia (CML) was one of the first examples of a molecular targeted therapy that is now being used for other cancers. Today, someone with CML who is remission after treatment has the same life expectancy as someone who doesn't have cancer.

Discover Leuka Funded Research

Since 1982, Leuka has funded research into leukaemia and other blood cancer. Discover our funded projects.

Leuka Funded Research

Leuka Research Opportunities

We're supporting research that is accelerating the pace of development and aiming to bring new treatments and cures to patients as quickly as possible. Learn more about the research we fund. 

Nurse and patient with leukaemia - part of Leuka's leukaemia research and treatment

IMPACT Trials Partnership

research

We are proud to be a part of the IMPACT stem cell transplant clinical trials initiative. This partnership aims to bring new drug and cellular therapies to patients.

Increasingly, people with leukaemia and other blood cancers can benefit from the availability of Stem Cell Transplantation (SCT) treatments. However, all too often those who have undergone SCT will eventually succumb to adverse reactions from the procedure. Of those who receive a stem cell transplant from an unrelated donor, fewer than 50% of them will reach the 5-year survival milestone.

That is why we’ve invested in a new clinical trials initiative called IMPACT to fast-track the testing of drug and cellular therapies for patients who suffer complications. 

Working in partnership with Anthony Nolan and NHS Blood and Transplant, we launched the initiative in November 2017.

Based at the University of Birmingham, the IMPACT partnership will work alongside specialist centres around the UK to provide the infrastructure for early phase clinical trials.

More about IMPACT